Juventas Therapeutics is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials. Investors include Triathlon Medical Venture Partners, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received nondilutive grant support through the Ohio Third Frontier funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine.

Cube Srl is a private company headquartered in Italy that provides advertising services.

Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint of biological system to reveal novel discoveries and realize the promise of precision medicine. The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions. Metabolon was founded in 2000 and headquartered in Durham, North Carolina.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Barts Health NHS Trust is a company headquartered in London, UK and ultimately controlled by the Government of United Kingdom, that provides health services.\nThe company says this about itself: Barts Health NHS Trust operates four acute hospitals (The Royal London, St Bartholomew's, Whipps Cross, and Newham) and a number of community locations, including Mile End hospital. The group provides healthcare services for about 2.5 million people living in east London.

CardioPolymers is a developer of an implantable device for treating congestive heart failure. It provides biocompatible polymer implant therapies to handle chronic heart failure, mitral valve regurgitation, and postoperative atrial fibrillation.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Recombinetics is a developer of gene editing technologies to improve human health through advanced disease models and regenerative medicine. Its gene-editing technologies manipulate deoxyribonucleic acid (DNA) samples to add and activate genes to solve problems and also offer gene repair and gene editing tools that enable biomedical research, livestock productivity, animal agriculture, and livestock vertical markets to modify animal genomes accurately and efficiently.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Centro Cardiologico Monzino SpA engages in the treatment, research, and study of cardiovascular diseases. Its clinical activities include interventional cardiology, cardiovascular surgery, cardiac imaging, and diagnostic laboratory services. The company was founded by Italo Monzino and Cesare Bartorelli in 1981 and is headquartered in Milan, Italy.

BPGbio Inc is an American private company located in Framingham, MA, that engages in biotechnology research activities. Niven R. Narain is currently the CEO of the firm.\nThe company says this about itself: Headquartered in the greater Boston, Massachusetts area, BPGbio, Inc., is a leading AI-powered biopharmaceutical company with a human biology focus. BPGbio leverages its Interrogative Biology® platform, along with one of the world’s largest non-governmental, clinically and multi-omics annotated human biorepositories, to redefine how patient biology can be modeled using unbiased AI. This approach accelerates and de-risks the process of drug discovery across oncology, neurology, and rare diseases.

Techno Network Shikoku connects universities and private companies to develop technologies and solve problems.

Advanced Cardiovascular Systems, Inc. develops and manufactures cardiovascular medical products. It operates as a subsidiary of Abbott Laboratories. Its medical devices help patients with heart diseases in returning to active and productive lives and physicians for improving patient management and clinical outcomes. Advanced Cardiovascular Systems, Inc. is based in Santa Clara, California. it is currently known as Abbott Cardiovascular Systems.

Hangzhou Nuocheng Medical Equipment Co., Ltd., established on 2017-11-09, Business scope includes technology development,technical consulting:medical technology,medical instruments;wholesale,retail:Class I medical device,Class II medical device,Class III medical devices;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough, and Biogen Idec. The company was established in 2001 and is based in Cambridge, Massachusetts.

Shanghai Yudan Pharmaceutical Co., Ltd., established on 1993-09-23, The business scope includes hard capsules,pill,Chinese medicine extraction workshop.Technical consultation in the field of pharmaceutical production technology,Technical Services. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]